Active

Developing a new class of anti-cancer drug

Cancer types:

General cancer research

Project period:

Research institute:

University of Auckland

Award amount:

£182,321

Location:

New Zealand

Researcher Dr Jo K Perry

Dr Perry is studying a potential new therapy for several types of cancer that target the growth hormone signalling pathway and could be particularly effective in patients that also undergo radiotherapy.

The science

Some of the most successful strategies for treating cancer have involved the use of targeted therapies such as monoclonal antibodies. Monoclonal antibodies work by detecting and blocking specific proteins that help cancers grow and spread. These therapies can be very effective when combined with chemotherapy or radiotherapy. Radiotherapy, while an important treatment route for many cancers, doesn’t work for all patients. One approach to improve the effectiveness of radiotherapy is to combine it with radiosensitising drugs that make cancer cells more vulnerable to radiation by targeting their crucial growth and survival mechanisms.


Dr Perry and her team are now trying to improve radiotherapy by targeting growth hormone signalling in cancer cells. Abnormal levels of growth hormone can be detected in some breast and endometrial cancers and this is associated with worse patient outcomes. Blocking growth hormone function could make tumour cells more sensitive to radiotherapy. Dr Perry and her team generated several monoclonal antibodies that can stop the growth hormone receptor from working. They are now trying to understand which of these antibodies could be taken into clinical development. If successful, this growth hormone-targeted antibody could benefit a wide range of cancer patients. 

Related projects

Active Spain

Lung cancer

How do cancer cells modify white blood cells to help tumours grow?

Researchers want to help immunotherapy work for more cancer patients by understanding how cancers hijack our immune system and preventing this happening 

Researcher: Dr Andrés Hidalgo

Understanding how cancer cells modify white blood cells to help tumours grow

Active United Kingdom

General cancer research

Can we stop cancer becoming resistant to chemotherapy?

Chemotherapy can sometimes stop working, so this project is hoping to better understand why and find ways to give more, better options to cancer patients.

Researcher: Dr Andrew Beekman

Stopping cancer becoming resistant to chemotherapy

Active United Kingdom

General cancer research

Can we predict which patients will respond to immunotherapy?

This project hopes to open up exciting possibilities for personalised cancer treatment by finding how to predict which patients will respond best to treatment.

Researcher: Professor Tim Elliott

Finding ways to predict which patients will respond to immunotherapy
Share this page